[HTML][HTML] Unmet needs and challenges in gastric cancer: the way forward

F Lordick, W Allum, F Carneiro, E Mitry… - Cancer treatment …, 2014 - Elsevier
Although the incidence of gastric cancer has fallen steadily in developed countries over the
past 50 years, outcomes in Western countries remain poor, primarily due to the advanced …

[HTML][HTML] New ultrasound techniques for lymph node evaluation

XW Cui, C Jenssen, A Saftoiu, A Ignee… - World Journal of …, 2013 - ncbi.nlm.nih.gov
Conventional ultrasound (US) is the recommended imaging method for lymph node (LN)
diseases with the advantages of high resolution, real time evaluation and relative low costs …

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally …

SE Al-Batran, N Homann, C Pauligk, TO Goetze… - The Lancet, 2019 - thelancet.com
Background Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-
oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the …

Laparoscopic versus open gastrectomy for gastric cancer (LOGICA): a multicenter randomized clinical trial

A van der Veen, HJF Brenkman… - Journal of Clinical …, 2021 - ascopubs.org
BACKGROUND The oncological efficacy and safety of laparoscopic gastrectomy are under
debate for the Western population with predominantly advanced gastric cancer undergoing …

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

E Van Cutsem, YJ Bang, F Feng-Yi, JM Xu, KW Lee… - Gastric cancer, 2015 - Springer
Abstract Background In the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus
chemotherapy improved median overall survival by 2.7 months in patients with human …

Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized …

S Lorenzen, TO Götze, P Thuss-Patience… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE This trial evaluates the addition of the PD-L1 antibody atezolizumab (ATZ) to
standard-of-care fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) as a …

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone

JH Kang, SI Lee, DH Lim, KW Park, SY Oh… - Journal of Clinical …, 2012 - ascopubs.org
Purpose When designing this trial, there was no evidence that salvage chemotherapy (SLC)
in advanced gastric cancer (AGC) resulted in substantial prolongation of survival when …

FLOT versus FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2–positive resectable esophagogastric …

RD Hofheinz, K Merx, GM Haag… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE High pathologic complete response (pCR) rates and comparably good survival
data were seen in a phase II trial combining perioperative fluorouracil, leucovorin …

Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment

S Thies, R Langer - Frontiers in oncology, 2013 - frontiersin.org
Multimodal therapy concepts have been successfully implemented in the treatment of locally
advanced gastrointestinal malignancies. The effects of neoadjuvant chemo-or …

[HTML][HTML] Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer–differential …

MP Lutz, JR Zalcberg, M Ducreux, JA Ajani… - European journal of …, 2012 - Elsevier
The 1st St. Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel clearly
differentiated treatment and staging recommendations for the various gastroesophageal …